Adoptive immunotherapy for postoperative hepatocellular carcinoma: A systematic review

International Journal of Clinical Practice

Volumn 66, Issue 1, 2012, Pages 21-27

  Zhong, J H ^a   Ma, L ^a   Wu, L C ^a   Zhao, W ^a   Yuan, W P ^a   Wu, F X ^a   Zhang, Z M ^a   Huang, S ^a   You, X M ^a   Li, L Q ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIBODY; DOXORUBICIN; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; CANCER ADJUVANT THERAPY; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DISEASE FREE SURVIVAL; DIZZINESS; DONOR LYMPHOCYTE INFUSION; DRUG RESPONSE; FEVER; HEADACHE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; NAUSEA; OVERALL SURVIVAL; PATIENT SAFETY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT OUTCOME; TUMOR ABLATION;

ADJUVANTS, IMMUNOLOGIC; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 83755174655     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02814.x     Document Type: Review

References (53)

1. El-Serag HB,. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127 (5 Suppl 1): S27-34. (Pubitemid 39423367)
2. Bosetti C, Levi F, Boffetta P, et al., Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008; 48: 137-45. (Pubitemid 351980469)
3. Parikh S, Hyman D,. Hepatocellular cancer: a guide for the internist. Am J Med 2007; 120: 194-202. (Pubitemid 46341174)
4. Parkin DM, Bray F, Ferlay J, et al., Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
5. Maheshwari A, Kantsevoy S, Jagannath S, et al., Endoscopic ultrasound and fine-needle aspiration for the diagnosis of hepatocellular carcinoma. Clin Liver Dis 2010; 14: 325-32.
6. Colecchia A, Scaioli E, Montrone L, et al., Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. J Hepatol 2011; 54: 300-5.
7. Ikeda K, Kobayashi M, Seko Y, et al., Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: a retrospective study of hepatitis C virus-related liver cancer. Hepatol Res 2010; 40: 1168-75.
8. Wang GB, Zhou XY, Wang XQ,. Relationship between serum heparanase and microscopic venous invasion in patients with hepatocellular carcinoma. Am J Clin Pathol 2010; 134: 242-8.
9. Kaibori M, Ishizaki M, Matsui K, et al., Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma. J Surg Oncol 2010; 102: 462-8.
10. Funaki NO, Tanaka J, Seto SI, et al., Hematogenous spreading of hepatocellular carcinoma cells: possible participation in recurrence in the liver. Hepatology 1997; 25: 564-8. (Pubitemid 27106434)
11. Lai EC, Lau WY,. The continuing challenge of hepatic cancer in Asia. Surgeon 2005; 3: 210-5. (Pubitemid 40932721)
12. Llovet JM, Burroughs A, Bruix J,. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17. (Pubitemid 37518510)
13. Zhong JH, Li LQ,. Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis. Hepatol Res 2010; 40: 943-53.
14. Tan A, Aucejo F, Kim R,. Is there a role for adjuvant treatment after hepatic resection for hepatocellular carcinoma? Oncology 2010; 78: 161-71.
15. Yang JY, Cao DY, Ma LY, et al., Dendritic cells fused with allogeneic hepatocellular carcinoma cell line compared with fused autologous tumor cells as hepatocellular carcinoma vaccines. Hepatol Res 2010; 40: 505-13.
16. Zerbini A, Pilli M, Ferrari C, et al., Is there a role for immunotherapy in hepatocellular carcinoma? Dig Liver Dis 2006; 38: 221-5. (Pubitemid 44356180)
17. Butterfield LH,. Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology 2004; 127 (Suppl 51): S232-41. (Pubitemid 39423392)
18. Moher D, Cook DJ, Eastwood S, et al., Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999; 354: 1896-900.
19. Takayama T, Sekine T, Makuuchi M, et al., Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 2000; 356: 802-7.
20. Dong H, LI Q, Wang J, et al., A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 2009; 41: 36-41.
21. Weng DS, Zhou J, Zhou QM, et al., Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother 2008; 31: 63-71. (Pubitemid 351619405)
22. Zhou WP, Wu MC, Chen H,. [The effects of combined hepatectomy and immuno-chemotherapy on postoperative recurrence rate of primary liver cancer]. Zhonghua Wai Ke Za Zhi 1995; 33: 35-7.
23. Kawata A, Une Y, Hosokawa M, et al., Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone. Am J Clin Oncol 1995; 18: 257-62.
24. Xie L, Pang R, Jin Y, et al., [Effects of hepatic artery chemotherapeutic embolization combined with perfusing LAK cells into hepatic artery after radical operation of liver cancer]. Zhonghua Gan Zang Bing Za Zhi 2000; 8: 142-3.
25. Ma H, Zhang Y, Wang Q, et al., Therapeutic safety and effects of adjuvant autologous RetroNectin activated killer cell immunotherapy for patients with primary hepatocellular carcinoma after radiofrequency ablation. Cancer Biol Ther 2010; 9: 903-7.
26. Wang Y, Chen H, Wu M, et al., Postoperative immunotherapy for patients with hepatocarcinoma using tumor-infiltrating lymphocytes. Chin Med J (Engl) 1997; 110: 114-7. (Pubitemid 27139428)
27. Takeda T, Watanabe M, Umeshita K, et al., [Long-term prognosis of hepatocellular carcinoma patients treated with adoptive immunotherapy]. Gan To Kagaku Ryoho 2004; 31: 1646-8.
28. Taieb J, Barbare JC, Rougier P,. Medical treatments for hepatocellular carcinoma (HCC): what's next? Ann Oncol 2006; 17 (Suppl 10): x308-14. (Pubitemid 44542028)
29. Morse MA, Clay TM, Lyerly HK,. Current status of adoptive immunotherapy of malignancies. Expert Opin Biol Ther 2002; 2: 237-47. (Pubitemid 34464806)
30. Yamaguchi Y, Ohshita A, Kawabuchi Y, et al., Adoptive immunotherapy of cancer using activated autologous lymphocytes - current status and new strategies. Hum Cell 2003; 16: 183-9.
31. Wang FS, Liu MX, Zhang B, et al., Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol 2002; 8: 464-8. (Pubitemid 34692743)
32. Ladhams A, Schmidt C, Sing G, et al., Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 2002; 17: 889-96.
33. Ohira M, Ohdan H, Mitsuta H, et al., Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy. Transplantation 2006; 82: 1712-9. (Pubitemid 46035657)
34. Cao ZX, Chen XP, Wu ZD,. Changes of immune function in patients with liver cirrhosis after splenectomy combined with resection of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2003; 2: 562-5.
35. Maksan SM, Araib PM, Ryschich E, et al., Immune escape mechanism: defective resting and stimulated leukocyte-endothelium interaction in hepatocellular carcinoma of the rat. Dig Dis Sci 2004; 49: 859-65. (Pubitemid 38870215)
36. Ritter M, Ali MY, Grimm CF, et al., Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma. J Hepatol 2004; 41: 999-1007. (Pubitemid 39575668)
37. Okada S, Abo T,. Spontaneous regression of hepatocellular carcinoma. J Gastroenterol Hepatol 2000; 15: 965-6.
38. Shi M, Zhang B, Tang ZR, et al., Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004; 10: 1146-51. (Pubitemid 38559390)
39. Olioso P, Giancola R, Di Riti M, et al., Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 2009; 27: 130-9.
40. Cai L, Zhang Z, Zhou L, et al., Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 2008; 129: 428-37.
41. Ono K, Yamanaga Y, Yamamoto K, et al., Natural killing activities in chronic liver diseases and hepatocellular carcinoma. J Clin Immunol 1996; 16: 41-5. (Pubitemid 26043025)
42. Sawayama T, Sakaguchi K, Senoh T, et al., Effects of pulsing procedure of interleukin-12 in combination with interleukin-2 on the activation of peripheral blood lymphocytes derived from patients with hepatocellular carcinoma. Acta Med Okayama 2003; 57: 285-92. (Pubitemid 38142749)
43. Ostapenko VV, Tanaka H, Miyano M, et al., Immune-related effects of local hyperthermia in patients with primary liver cancer. Hepatogastroenterology 2005; 52: 1502-6. (Pubitemid 41391025)
44. Zerbini A, Pilli M, Laccabue D, et al., Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology 2010; 138: 1931-42.
45. Doskali M, Tanaka Y, Ohira M, et al., Possibility of adoptive immunotherapy with peripheral blood-derived CD3CD56 + and CD3 + CD56 + cells for inducing antihepatocellular carcinoma and antihepatitis C virus activity. J Immunother 2011; 34: 129-38.
46. Pang YL, Zhang HG, Peng JR, et al., The immunosuppressive tumor microenvironment in hepatocellular carcinoma. Cancer Immunol Immunother 2009; 58: 877-86.
47. Bohne F, Chmielewski M, Ebert G, et al., T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology 2008; 134: 239-47. (Pubitemid 350309333)
48. Shi M, Fu J, Shi F, et al., Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection. Clin Immunol 2009; 132: 43-54.
49. Llovet JM, Ricci S, Mazzaferro V, et al., Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
50. Cheng AL, Kang YK, Chen Z, et al., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
51. Lord R, Suddle A, Ross PJ,. Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies. Int J Clin Pract 2011; 65: 182-8.
52. Lencioni R, Marrero J, Venook A, Ye SL, Kudo M,. Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study. Int J Clin Pract 2010; 64: 1034-41.
53. Greten TF, Korangy F,. Radiofrequency ablation for the treatment of HCC - maybe much more than simple tumor destruction? J Hepatol 2010; 53: 775-6.